![]() |
市場調查報告書
商品編碼
1662772
2030 年伴同性動物診斷市場預測:按產品類型、動物類型、診斷方法、應用、最終用戶和地區進行的全球分析Companion Animal Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type (Instruments, Reagents & Kits, Consumables, Software, and Other Product Types), Animal Type, Diagnostic Method, Application, End User and By Geography |
根據 Stratistics MRC 的數據,全球伴同性動物診斷市場預計在 2024 年將達到 59.2 億美元,到 2030 年將達到 113.2 億美元,預測期內的複合年成長率為 11.4%。
伴同性動物診斷是使用各種儀器、測試和方法診斷寵物(包括狗、貓和其他動物)的疾病的過程。該領域的獸醫專業人員使用臨床化學、分子診斷、免疫診斷、影像技術和實驗室測試來幫助早期發現疾病並追蹤治療效果。診斷技術的進步提高了疾病診斷的準確性和有效性,從而可以為伴同性動物提供更好的預防保健和治療選擇。
北美寵物健康保險協會估計,截至 2022年終,國內寵物保險用戶數量為 480 萬,比 2021 年增加 22%。
動物保健支出增加
寵物擁有量的快速成長,尤其是在已開發國家,正在推動對獸醫服務的需求。寵物飼主擴大投資於寵物的健康和福利,因為他們將寵物視為家庭的一部分。獸醫學和診斷技術(如影像和分子診斷)的改進將提高早期疾病檢測的有效性並鼓勵人們在預防性治療上進行支出。此外,寵物慢性疾病的發生率不斷上升,以及人們對定期檢查益處的認知不斷提高,促使飼主願意為他們的寵物花錢購買醫療和診斷服務。
保險範圍限制
有限的診斷成本意味著許多飼主不願意為他們的動物尋求早期診斷和治療。這可能會導致嚴重的延遲檢測,從而對您的寵物的健康產生負面影響並最終導致更高的治療費用。此外,低收入家庭因缺乏全面保險而受到嚴重影響,限制了他們獲得尖端診斷設備和治療的機會。這限制了市場成長,阻礙了更廣泛的獸醫診斷方法的發展,可能導致疾病診斷不足、獸醫就診次數減少,最終導致寵物健康惡化。
擴建獸醫醫院和診所
隨著越來越多獸醫醫院的建立和最先進的診斷技術的安裝,對一流診斷設備和服務的需求將會增加。透過提供更廣泛的診斷測試,包括影像、分子診斷和臨床化學,這些擴展正在提高寵物護理的品質。規模更大、更專業的獸醫診所也能滿足越來越多想要獲得快速、徹底預防性護理的飼主的需求。獸醫行業的興起推動了尖端診斷服務和產品的採用,從而帶來了診斷解決方案的創新。
缺乏訓練有素的專業人員
伴同性動物診斷行業合格人才的短缺嚴重阻礙了獸醫服務的品質和可及性。如果沒有足夠資格的獸醫和實驗室專業人員,就很難準確、快速地檢測寵物的健康問題,從而導致誤診和延誤治療。這種短缺也會使先進的診斷設備難以有效使用,因為需要熟練的人員來解釋結果並操作複雜的設備。此外,缺乏訓練有素的人員的地區可能會面臨診斷服務價格更高、等待時間更長的問題,從而降低伴同性動物醫學的整體有效性,並阻礙尖端診斷工具的採用。
COVID-19 的影響
COVID-19 疫情以多種方式影響了伴同性動物診斷市場。最初,由於人類健康問題和診所就診機會有限,封鎖和限制措施導致獸醫諮詢和診斷程序減少。然而,隨著疫情期間寵物擁有量激增,對寵物醫療保健的需求也隨之增加,增加了對診斷服務的需求。此外,疫情凸顯了預防保健的重要性,並導致人們長期轉向對寵物進行定期診斷檢查。
預計預測期內消耗品部分將成長至最大的部分。
由於需要對寵物進行持續的健康監測以及標準診斷測試的增加,預計預測期內消耗品部分將佔據最大的市場佔有率。常規診斷程序需要試劑、檢測套組和樣本收集材料等消耗品。隨著獸醫醫院和診所擴大其診斷能力,對可靠的一次性耗材的需求不斷增加,推動了市場擴張。照護現場診斷的創新也推動了對耗材的需求。
預計預測期內,獸醫院部門將以最高的複合年成長率成長。
預計預測期內獸醫院部門將呈現最高成長率。隨著寵物飼主越來越關注寵物的健康以及寵物擁有率的上升,診所對診斷服務的需求也增加。這需要這些診所配備先進的診斷設備和工具。隨著寵物保險覆蓋範圍的擴大以及飼主尋求更全面的治療(通常包括診斷測試),市場正在擴大。
由於可支配收入的增加和人們對寵物保健認知的提高,預計亞太地區將在預測期內佔據最大的市場佔有率。隨著獸醫基礎設施的不斷擴大和先進診斷工具的普及,越來越多的飼主希望定期為寵物進行健康檢查。這一趨勢推動了對診斷服務的需求,刺激了技術創新並刺激了市場擴張,尤其是在中國和印度等國家。
由於寵物擁有率高且對寵物健康和保健的興趣日益濃厚,預計北美在預測期內的複合年成長率最高。寵物飼主越來越尋求先進的診斷解決方案,推動了對分子診斷和成像工具等最尖端科技的需求。這一趨勢導致獸醫院和診所的擴張,從而刺激市場成長。此外,可支配收入的增加也導致寵物醫療保健和診斷支出的增加。
According to Stratistics MRC, the Global Companion Animal Diagnostics Market is accounted for $5.92 billion in 2024 and is expected to reach $11.32 billion by 2030 growing at a CAGR of 11.4% during the forecast period. Companion animal diagnostics is the process of diagnosing illnesses and ailments in pets, including dogs, cats, and other animals, using a variety of instruments, examinations, and methods. Veterinary professionals use clinical chemistry, molecular diagnostics, immunodiagnostics, imaging technologies, and laboratory testing in this sector to assist identify diseases early, track the effectiveness of treatments. Better preventative care and treatment choices for companion animals are made possible by improvements in diagnostics, which increase the precision and effectiveness of ailment diagnosis.
According to the data published by the North American Pet Health Insurance Association Inc., in 2023, the total premium volume for pet insurance in the country was USD 3.2 billion. The total number of pets insured in the country at year-end 2022 was 4.8 million, a 22% increase since 2021.
Increase in animal healthcare spending
Veterinary services are in greater demand as a result of the sharp increase in pet ownership, particularly in developed nations. Owners are more inclined to make investments in their pets' health and wellbeing as they are increasingly seen as part of the family. Improvements in veterinary medicine and diagnostic technology, like imaging and molecular diagnostics, increase the efficacy of early disease identification and promote spending on preventative treatment. Pet owners' willingness to spend more money on medical care and diagnostic services for their animals is also encouraged by the growing prevalence of chronic diseases in pets and increased awareness of the advantages of routine checkups.
Limited insurance coverage
Financial limitations for diagnostic procedures can discourage many pet owners from seeking early diagnosis or treatment for their animals. This may result in the delayed identification of severe medical disorders, which could have a detrimental effect on the pet's health and ultimately raise treatment expenses. Additionally, lower-income households are disproportionately impacted by the lack of comprehensive insurance alternatives, which restricts their access to cutting-edge diagnostic equipment and care. This could restrict market growth and impede the development of more widely available veterinary diagnostics, leading to an under diagnosis of diseases, fewer veterinary visits, and ultimately worse health outcomes for pets.
Expansion of veterinary clinics and hospitals
The demand for top-notch diagnostic equipment and services rises as more veterinary clinics are built and outfitted with cutting-edge diagnostic technologies. By providing a wider range of diagnostic tests, including imaging, molecular diagnostics, and clinical chemistry, these enlarged facilities can improve the quality of pet healthcare. Larger and more specialized veterinary clinics also serve the increasing number of pet owners who want prompt, thorough, and preventative care for their animals. The adoption of cutting-edge diagnostic services and products is fuelled by the rise of the veterinary industry and offers chances for diagnostic solution innovation.
Shortage of trained professionals
The quality and accessibility of veterinary services are seriously hampered by the lack of qualified personnel in the companion animal diagnostics industry. It becomes more difficult to detect pet health issues accurately and promptly when there are insufficiently qualified veterinarians and laboratory professionals, which can result in misdiagnosis or delayed treatments. Because skilled personnel are needed to interpret results and operate complicated equipment, this shortage may also make it more difficult to use advanced diagnostic instruments effectively. Furthermore, areas with a shortage of trained personnel may see higher diagnostic service charges and longer wait times, which would lower the overall efficacy of companion animal healthcare and impede the uptake of state-of-the-art diagnostic tools.
Covid-19 Impact
The COVID-19 pandemic had a mixed impact on the companion animal diagnostics market. Initially, lockdowns and restrictions led to a decrease in veterinary visits and diagnostic procedures due to concerns about human health and limited access to clinics. However, as pet ownership surged during the pandemic, the demand for pet healthcare increased, fueling the need for diagnostic services. Additionally, the pandemic highlighted the importance of preventive care, leading to a long-term shift toward more routine diagnostic check-ups for pets.
The consumables segment is expected to be the largest during the forecast period
The consumables segment is expected to account for the largest market share during the forecast period, due to the necessity of ongoing pet health monitoring and the rise in standard diagnostic testing. For routine diagnostic procedures, consumables such reagents, test kits, and sample collection materials are necessary. The demand for dependable, disposable consumables increases as veterinary clinics and hospitals broaden their diagnostic capabilities, which fuels market expansion. Innovations in point-of-care diagnostics also increase the demand for consumables.
The veterinary clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the veterinary clinics segment is predicted to witness the highest growth rate. Clinics witness an increase in demand for diagnostic services as pet owners become more involved in the health of their animals and pet ownership rises. This makes sophisticated diagnostic equipment and tools necessary in these clinics. The market is growing because pet owners are encouraged to seek more thorough treatment, which frequently includes diagnostic testing, by the increase in pet insurance coverage.
During the forecast period, Asia Pacific region is expected to hold the largest market share, due to rising disposable incomes, and improving awareness of pet healthcare. With expanding veterinary infrastructure and greater access to advanced diagnostic tools, more pet owners are seeking regular health check-ups for their animals. This trend is driving demand for diagnostic services, fostering innovation, and encouraging market expansion, particularly in countries like China and India.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to high pet ownership and a strong focus on pet health and wellness. Pet owners are increasingly seeking advanced diagnostic solutions, driving demand for cutting-edge technologies like molecular diagnostics and imaging tools. This trend has led to the expansion of veterinary clinics and hospitals, encouraging growth in the market. Additionally, rising disposable incomes contribute to increase spending on pet healthcare and diagnostics.
Key players in the market
Some of the key players profiled in the Companion Animal Diagnostics Market include Idexx Laboratories, Inc., Thermo Fisher Scientific, Inc., Heska Corporation, Virbac, Elanco Animal Health, Randox Laboratories, Zoetis Inc., Boehringer Ingelheim, Medi-Lab, VCA Animal Hospitals, Neogen Corporation, Horizon Veterinary Diagnostics, BioNote, Inc., Reflxion, and Agrolabo S.P.A.
In December 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the GibcoCTS(TM) Detachable Dynabeads(TM) CD4 and CTS Detachable Dynabeads CD8. These latest products expand on Thermo Fisher's CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while also creating greater workflow control.
In December 2024, IDEXX Laboratories, Inc. announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market or in negotiated transactions.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.